Aditxt CEO presents autoimmunity unit Adimune; stock at $5M market cap

Aditxt, Inc.

CEO presented at Wall Street Reporter livestream on July 22, 2025, focusing on subsidiary Adimune.
Adimune aims to reprogram immune system for autoimmune diseases; currently preclinical with human trials as key catalyst.
Other catalysts: Pearsanta cancer detection spin-off IPO and Adifem (Evofem) acquisition close expected Sept 2025.
CEO believes stock's ~$5M market cap is disconnected from value proposition; multiple shots on goal.
Adimune approach contrasts with traditional immunosuppressants; results from human trials awaited.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.